Generic Dolutegravir

Buy Generic Dolutegravir () without prescription in Canada

In our Canadian pharmacy, you can buy Dolutegravir without a prescription, with delivery across Canada within 5‑14 days. Discreet and anonymous packaging.

Dolutegravir is an antiretroviral medication belonging to the integrase strand transfer inhibitor (INSTI) class. It is used in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV‑1) infection in adults and children. Dolutegravir works by binding to the integrase active site and blocking the strand transfer step of retroviral DNA integration, a critical step in the HIV replication cycle. This prevents the viral genome from integrating into the host cell DNA, thereby halting viral replication and reducing the viral load to undetectable levels when used as part of effective combination therapy.

Usual adult dose: The recommended dose for treatment‑naïve or treatment‑experienced, integrase strand transfer inhibitor‑naïve patients is 50 mg taken orally once daily. For patients with documented or clinically suspected integrase strand transfer inhibitor resistance (e.g., certain INSTI‑resistance mutations), the dose should be increased to 50 mg twice daily, taken with food to enhance absorption and maintain effective plasma concentrations. Dolutegravir should always be administered in combination with other antiretroviral agents. The tablet may be taken with or without food for the once‑daily regimen, but when taken twice daily for resistance, it must be taken with a meal to ensure adequate drug exposure.

Dosage form: Oral film‑coated tablet, 50 mg (as dolutegravir sodium).

Onset of action: A rapid decline in plasma HIV‑1 RNA (viral load) is typically observed within the first 1 to 2 weeks of initiating combination antiretroviral therapy that includes dolutegravir. Maximal virologic suppression (viral load below the limit of detection) is usually achieved after 12 to 24 weeks of consistent daily dosing, depending on baseline viral load and adherence.

Duration of action: Dolutegravir has an elimination half‑life of approximately 14 hours, supporting once‑daily dosing. Its antiretroviral effect is sustained as long as the medication is taken regularly; missed doses can lead to viral rebound and the development of drug resistance.

Alcohol recommendation: Alcohol consumption should be limited or avoided during treatment with Dolutegravir. While there is no direct pharmacokinetic interaction, alcohol can impair liver function and may increase the risk of hepatotoxicity, particularly in patients co‑infected with hepatitis B or C. Heavy alcohol use also interferes with medication adherence and overall health.

Most common side effects: Insomnia, headache, nausea, diarrhoea, fatigue, and dizziness. These effects are generally mild to moderate and often resolve within the first few weeks of therapy. Rare but serious adverse effects include hypersensitivity reactions (rash, constitutional symptoms, organ dysfunction), hepatotoxicity (elevated liver enzymes, hepatitis, and hepatic failure, particularly in patients with hepatitis B or C co‑infection), and immune reconstitution inflammatory syndrome (IRIS). An early embryonic signal from a single observational study suggested a possible increased risk of neural tube defects in infants born to women who were taking dolutegravir at the time of conception; current data indicate a low but statistically significant risk. Women of childbearing potential should undergo pregnancy testing before initiating dolutegravir and use effective contraception during treatment.

Would you like to try Dolutegravir without a prescription?

General Information about Dolutegravir

• INN (International Nonproprietary Name): Dolutegravir (as dolutegravir sodium).
• Brand names available in Canada: Tivicay® (ViiV Healthcare ULC) is the brand‑name product. Generic versions are available and include APO‑Dolutegravir (Apotex Inc.), TEVA‑Dolutegravir (Teva Canada Limited), and other manufacturer‑branded generics. Dolutegravir is also a component of the fixed‑dose combinations Triumeq® (abacavir/dolutegravir/lamivudine), Juluca® (dolutegravir/rilpivirine), and Dovato® (dolutegravir/lamivudine).
• ATC code: J05AJ03 (dolutegravir; integrase inhibitors).
• Dosage forms and strengths: Oral film‑coated tablets: 10 mg, 25 mg, and 50 mg (as dolutegravir sodium). The 50 mg tablet is the standard adult once‑daily dose.
• Manufacturers in Canada: ViiV Healthcare ULC, Apotex Inc., Teva Canada Limited, and other generic manufacturers.
• Registration status in Canada: Approved by Health Canada. Tivicay received its Notice of Compliance on November 4, 2013. DINs: 02424480 (Tivicay 50 mg), among others. Multiple generic formulations are currently marketed and available by prescription.
• OTC / Rx classification: Prescription only (Rx). Schedule I drug under the Controlled Drugs and Substances Act. Dolutegravir must be prescribed by a licensed Canadian healthcare professional experienced in the management of HIV infection.

Mechanism of Action and Pharmacology

Dolutegravir is an inhibitor of the HIV‑1 integrase enzyme. Integrase is responsible for two critical steps in the HIV replication cycle: 3′‑processing of viral DNA and the subsequent strand transfer into the host cell genome. Dolutegravir binds to the integrase active site, chelates the divalent metal ions (Mg²⁺) required for enzymatic activity, and specifically blocks the strand transfer step. By preventing the integration of viral DNA, dolutegravir halts the production of new infectious viral particles. It retains activity against many integrase resistance mutations and demonstrates a high genetic barrier to resistance.

Following oral administration, dolutegravir is rapidly absorbed, with peak plasma concentrations achieved 2 to 3 hours after a dose. The absolute bioavailability is approximately 63% when taken without food; a high‑fat meal increases the area under the curve (AUC) by about 33–66%, but this is not clinically significant for the once‑daily dose. For the twice‑daily dose (in the setting of integrase resistance), food is recommended to ensure adequate trough concentrations. Dolutegravir is approximately 99% bound to plasma proteins. It is metabolised primarily by UDP‑glucuronosyltransferase 1A1 (UGT1A1), with a minor contribution from cytochrome P450 3A4 (CYP3A4). The elimination half‑life is approximately 14 hours. The drug is excreted mainly in the faeces (53%) and urine (31%), predominantly as unchanged dolutegravir and its ether glucuronide metabolite. Dolutegravir inhibits the renal organic cation transporter 2 (OCT2), which can increase plasma concentrations of drugs that are OCT2 substrates (e.g., metformin). It also inhibits the multidrug and toxin extrusion transporter 1 (MATE1) to a lesser extent.

Indications

• Treatment of human immunodeficiency virus type 1 (HIV‑1) infection in adults and children weighing at least 3 kg, in combination with other antiretroviral agents. Dolutegravir has demonstrated potent virologic suppression in both treatment‑naïve and treatment‑experienced patients, including those with resistance to other integrase inhibitors.
• Dolutegravir is not a cure for HIV infection or AIDS. It does not reduce the risk of transmitting HIV to others. Patients must continue to practise safe sex and other precautions.
• Not indicated for the treatment of HIV‑2 unless in combination with other active agents, although in vitro data suggest activity.

Important Warnings and Precautions

At‑risk groups

• Pregnancy and fetal risk: An early observational study (Tsepamo) in Botswana reported an increased incidence of neural tube defects (NTDs) in infants born to women who were taking dolutegravir at the time of conception. More recent data suggest a small but statistically significant absolute risk of approximately 0.19% (about 2 cases per 1,000 births) compared with approximately 0.10% for other antiretroviral regimens. Health Canada recommends that women of childbearing potential undergo pregnancy testing before initiating dolutegravir, and effective contraception must be used throughout treatment. The choice of antiretroviral regimen during pregnancy and in women planning to conceive should be made in consultation with an HIV specialist, weighing the potent antiviral benefit of dolutegravir against the low absolute risk of NTDs. Dolutegravir can be used during the second and third trimesters when the expected benefit justifies the potential risk; folic acid supplementation is advised for all women of childbearing potential.
• Breastfeeding: Dolutegravir is excreted in human breast milk at low levels. In Canada, HIV‑infected women are advised not to breastfeed, irrespective of antiretroviral therapy, in order to avoid postnatal transmission of HIV to the infant. Breastfeeding is contraindicated.
• Paediatrics: Safety and efficacy have been established for children weighing at least 3 kg. Weight‑based dosing is used: for children weighing 3 to < 6 kg, the dose is 5 mg once daily; for 6 to < 10 kg, 15 mg once daily; for 10 to < 14 kg, 20 mg once daily; for 14 to < 20 kg, 25 mg once daily; and for ≥ 20 kg, 50 mg once daily. Paediatric dosing must be determined by a specialist.
• Elderly: No dose adjustment is required based on age alone. However, elderly patients may have decreased hepatic, renal, or cardiac function, and concomitant disease or drug therapy; they should be monitored carefully.
• Hepatic impairment: No dose adjustment is required in patients with mild to moderate hepatic impairment (Child‑Pugh A or B). Dolutegravir has not been studied in patients with severe hepatic impairment (Child‑Pugh C) and should be used with caution.
• Renal impairment: No dose adjustment is required in patients with renal impairment, including those with end‑stage renal disease on haemodialysis. Dolutegravir is not significantly removed by haemodialysis.
• Hypersensitivity reactions: Hypersensitivity reactions characterized by rash, constitutional symptoms (fever, myalgia, malaise), and sometimes organ dysfunction (including liver injury, renal insufficiency) have been reported with dolutegravir. These reactions usually occur within the first few weeks of treatment. Patients should be closely monitored, and dolutegravir should be discontinued immediately if signs or symptoms of a hypersensitivity reaction develop. Clinical status, including liver transaminases, should be evaluated.
• Hepatotoxicity: Elevations in hepatic transaminases and bilirubin have been observed in patients taking dolutegravir‑containing regimens. Patients with pre‑existing liver disease, particularly those co‑infected with hepatitis B or C, are at increased risk. Liver function tests should be performed before starting therapy and periodically during treatment. If significant liver injury develops, dolutegravir should be discontinued.
• Immune Reconstitution Inflammatory Syndrome (IRIS): During the initial phase of combination antiretroviral therapy, patients responding to treatment may develop an inflammatory response to indolent or residual opportunistic infections (e.g., Mycobacterium avium complex, cytomegalovirus, Pneumocystis jirovecii pneumonia, or tuberculosis), which may necessitate further evaluation and treatment. Autoimmune disorders (such as Graves’ disease, polymyositis, and Guillain‑Barré syndrome) have also been reported in the setting of immune reconstitution; the time to onset is more variable and can occur many months after starting treatment.
• Drug interactions with metformin: Dolutegravir inhibits the OCT2 transporter, which can increase plasma concentrations of metformin. The dose of metformin may need to be reduced, and patients should be monitored for signs of metformin toxicity (e.g., lactic acidosis).
• Allergy: Do not take Dolutegravir if you have a known hypersensitivity to dolutegravir or any excipient in the tablet formulation.

Driving and alcohol

Dolutegravir may cause dizziness and fatigue, which could impair the ability to drive or operate machinery. Patients should be cautious until they know how the medication affects them. Alcohol should be limited or avoided, particularly in patients co‑infected with viral hepatitis, because it can increase the risk of hepatotoxicity and may reduce adherence.

Dosage Instructions

• Standard adult dose (treatment‑naïve or integrase‑naïve): 50 mg taken orally once daily, with or without food. Must be combined with other antiretroviral agents.
• For patients with suspected or documented integrase strand transfer inhibitor resistance (e.g., certain INSTI‑resistance mutations): 50 mg taken orally twice daily, with food. This higher dose and the food requirement are necessary to maintain adequate trough concentrations in the setting of reduced antiviral susceptibility.
• Dose adjustments with co‑administered drugs: When co‑administered with strong UGT1A1/CYP3A4 inducers (e.g., rifampicin, efavirenz, fosamprenavir/ritonavir, tipranavir/ritonavir, carbamazepine, phenytoin, phenobarbital, or St. John’s wort), the dolutegravir dose should be increased to 50 mg twice daily in patients without integrase resistance. For patients with integrase resistance, alternative combinations that do not include these metabolic inducers should be considered.
• Administration: Swallow the tablet whole with a glass of water. For the once‑daily regimen, the tablet may be taken at any time of day, with or without food, but a consistent daily routine aids adherence. For the twice‑daily regimen, the doses should be taken approximately 12 hours apart, with food each time. Do not crush or chew the tablet.
• Missed dose: If a dose is missed, take it as soon as remembered on the same day. If it is close to the time of the next dose, skip the missed dose and resume the regular schedule. Do not double the dose.

Side Effects and Contraindications

• Very common side effects (≥ 10%): Nausea, diarrhoea, headache, and fatigue. Insomnia is also common, occurring in about 5‑10% of patients.
• Common side effects (1‑10%): Vomiting, abdominal pain, dizziness, rash, and pruritus. Elevations in creatine phosphokinase (CPK), liver transaminases (ALT/AST), and bilirubin have been observed.
• Uncommon but serious side effects: Hypersensitivity reactions (drug reaction with eosinophilia and systemic symptoms [DRESS], Stevens‑Johnson syndrome, toxic epidermal necrolysis, and anaphylaxis have been reported rarely). Acute liver injury including hepatic failure, particularly in patients with pre‑existing liver disease or co‑infection with hepatitis B or C. Immune reconstitution inflammatory syndrome (IRIS). Renal impairment (interstitial nephritis). Pancreatitis (rare).
• Laboratory abnormalities: Small increases in serum creatinine (due to inhibition of OCT2‑mediated tubular secretion of creatinine, without affecting glomerular filtration) have been observed; these are not clinically significant and do not reflect a true decline in renal function. Increases in CPK, ALT, and AST should be monitored.
• Contraindications: Known hypersensitivity to dolutegravir or any excipient. Breastfeeding is contraindicated in HIV‑infected women. Co‑administration with dofetilide is contraindicated due to the potential for life‑threatening arrhythmias.

Drug Interactions

• Dofetilide — contraindicated: Dolutegravir has the potential to increase plasma concentrations of dofetilide, which can cause serious and/or life‑threatening arrhythmias. Co‑administration is contraindicated.
• Metformin — dose adjustment required: Dolutegravir inhibits OCT2, increasing metformin exposure (AUC increased by about 79% and C_max by about 66%). Metformin doses should be adjusted when starting or stopping dolutegravir, and patients should be monitored for signs of metformin toxicity (lactic acidosis).
• Polyvalent cation‑containing products (antacids, laxatives, sucralfate, oral iron, oral calcium, oral magnesium, buffered medications): Simultaneous administration reduces dolutegravir absorption via chelation. Dolutegravir should be taken at least 2 hours before or 6 hours after these products. Alternatively, dolutegravir and the cation‑containing product can be taken together with a meal, which minimizes the interaction for once‑daily dolutegravir. For twice‑daily dolutegravir (integrase resistance), however, food alone may not sufficiently compensate, and doses should be separated as recommended.
• UGT1A1/CYP3A4 inducers (rifampicin, rifabutin, efavirenz, boosted protease inhibitors [fosamprenavir/ritonavir, tipranavir/ritonavir], carbamazepine, phenytoin, phenobarbital, oxcarbazepine, St. John’s wort): These drugs decrease dolutegravir plasma concentrations. In patients without integrase resistance, the dolutegravir dose should be increased to 50 mg twice daily. In patients with integrase resistance, these combinations should be avoided. Rifabutin does not require a dolutegravir dose adjustment.
• Antiretroviral agents: No clinically significant interactions have been observed with tenofovir disoproxil fumarate, tenofovir alafenamide, emtricitabine, lamivudine, abacavir, rilpivirine, atazanavir/ritonavir, darunavir/ritonavir, lopinavir/ritonavir, maraviroc, or enfuvirtide. Dolutegravir does not require dose adjustment when co‑administered with these agents, with the exception of boosted protease inhibitors, which induce UGT1A1 and may warrant twice‑daily dosing in the setting of integrase resistance.
• Oral contraceptives: Dolutegravir had no clinically significant effect on the pharmacokinetics of ethinyl estradiol or norelgestromin in a study of an oral contraceptive containing norgestimate and ethinyl estradiol. No dose adjustment of oral contraceptives is required.
• Methadone: Dolutegravir did not significantly alter methadone pharmacokinetics. No dose adjustment of methadone is required.
• Food and alcohol: Alcohol should be limited. Food is recommended for the twice‑daily dose to enhance absorption; for once‑daily dosing, it can be taken with or without food.

Practical Advice

• Administration: Take dolutegravir exactly as prescribed, at the same time(s) each day, as part of a complete combination antiretroviral regimen. Missing doses can lead to treatment failure and the development of drug resistance. The tablet should be swallowed whole; do not crush or chew. If you are taking polyvalent cations (antacids, calcium, iron, magnesium, zinc, or multivitamins), separate dolutegravir by at least 2 hours before or 6 hours after these products, or take them together with a meal if you are on the once‑daily dose (but for twice‑daily dosing, strict separation is advised).
• Monitoring: HIV viral load and CD4 cell count should be monitored regularly to assess treatment response. Liver function tests should be performed at baseline and periodically during therapy, especially in patients with hepatitis B or C co‑infection. Renal function should be assessed; note that a small, non‑progressive increase in serum creatinine is expected and does not indicate kidney damage. Pregnancy testing should be performed in women of childbearing potential before starting treatment and periodically thereafter.
• Storage: Store at room temperature (15‑30 °C) in a dry place, protected from moisture and light. Keep the bottle tightly closed. Keep out of the reach and sight of children.
• Lifestyle: Dolutegravir is not a cure for HIV. Continue to practise safe sex (use condoms) and do not share needles or other personal items that may be contaminated with blood. Maintain a healthy diet, exercise, and adhere to all medical appointments. Avoid heavy alcohol consumption and recreational drugs, which can harm the liver and interact with medications. Inform all healthcare providers, including dentists, that you are taking dolutegravir. Carry a list of your antiretroviral medications with you at all times.
• Missed dose: If you miss a dose, take it as soon as you remember on the same day. If it is almost time for your next dose, skip the missed dose and continue with your regular schedule. Do not double the dose.
• When to seek medical review: Contact your doctor immediately if you develop a rash with fever, blisters, mouth sores, red or swollen eyes, facial swelling, muscle or joint pain, severe fatigue, or signs of liver problems (jaundice, dark urine, right upper abdominal pain, nausea, vomiting). Seek emergency medical attention for difficulty breathing, swelling of the face or throat, or severe skin reactions. If you are a woman of childbearing potential and become pregnant or plan to become pregnant, inform your HIV specialist promptly; do not stop your antiretrovirals without medical advice, as this can cause harm to both you and the baby.
• Disposal: Return unused or expired medication to a pharmacy for safe disposal. Do not flush down the toilet or discard in household waste.

Alternative Medications

• Other integrase strand transfer inhibitors (INSTIs): Raltegravir (Isentress®) and elvitegravir (available as part of the fixed‑dose combination Stribild® or Genvoya®). Bictegravir (available as part of Biktarvy®) is another potent INSTI with a high genetic barrier to resistance. Dolutegravir is generally preferred over raltegravir and elvitegravir due to its higher genetic barrier to resistance and once‑daily dosing (without a booster).
• Protease inhibitors (PIs): Darunavir (Prezista®) boosted with ritonavir or cobicistat, and atazanavir (Reyataz®) boosted with ritonavir or cobicistat. PIs have a high genetic barrier to resistance and are used in both treatment‑naïve and treatment‑experienced patients. They have more drug interactions and metabolic side effects than INSTIs.
• Non‑nucleoside reverse transcriptase inhibitors (NNRTIs): Rilpivirine (Edurant®, also in Complera®, Odefsey®, and Juluca®), doravirine (Pifeltro®, also in Delstrigo®), and efavirenz (Sustiva®, also in Atripla®). NNRTIs have a lower genetic barrier to resistance and may not be suitable for patients with high baseline viral loads.
• Nucleos(t)ide reverse transcriptase inhibitors (NRTIs): Tenofovir disoproxil fumarate (Viread®), tenofovir alafenamide, emtricitabine (Emtriva®), lamivudine (3TC), and abacavir (Ziagen®) form the backbone of most antiretroviral regimens. They are always used in combination with an INSTI, NNRTI, or PI.
• Fixed‑dose combinations: Dolutegravir is available as a single tablet in combination with abacavir and lamivudine (Triumeq®), with rilpivirine (Juluca®), and with lamivudine (Dovato®). These simplify the regimen to one or two pills once daily.

Clinical Efficacy

The efficacy of dolutegravir has been established in multiple Phase III randomised, controlled clinical trials in treatment‑naïve and treatment‑experienced adults. In the SPRING‑2 trial, dolutegravir 50 mg once daily was non‑inferior to raltegravir 400 mg twice daily, each combined with two NRTIs, achieving virologic suppression rates of 88% and 85%, respectively, at 48 weeks. In the SINGLE trial, dolutegravir plus abacavir/lamivudine was superior to efavirenz/tenofovir/emtricitabine, with 88% versus 81% achieving a viral load < 50 copies/mL at 48 weeks, largely due to fewer discontinuations for adverse events in the dolutegravir arm. In the VIKING‑3 and VIKING‑4 trials in patients with documented integrase resistance, dolutegravir 50 mg twice daily demonstrated potent activity, with approximately 69‑79% achieving virologic suppression at 24 weeks. Long‑term follow‑up studies have shown sustained viral suppression and a high barrier to resistance. Dolutegravir is recommended as a preferred component of first‑line antiretroviral therapy in Canadian and international HIV treatment guidelines, including those of the International Antiviral Society–USA (IAS‑USA) and the World Health Organization (WHO).

Important:

Dolutegravir (Tivicay) is a prescription antiretroviral medication that must be used under the supervision of a qualified healthcare professional experienced in the management of HIV infection. It does not cure HIV or AIDS and does not prevent transmission of the virus to others. Adherence to the prescribed regimen is critical; missing doses can lead to treatment failure and drug resistance. Serious hypersensitivity reactions have been reported; discontinue dolutegravir immediately and seek medical attention if you develop a rash with fever, blisters, mouth sores, red or swollen eyes, muscle or joint pain, or signs of liver injury. Women of childbearing potential should have a pregnancy test before starting treatment and use effective contraception, as there is a small but real risk of neural tube defects in babies born to mothers taking dolutegravir at conception. Do not take dolutegravir with dofetilide. If you are taking metformin, your dose may need to be adjusted. Separate dolutegravir from antacids, iron, calcium, or multivitamins by several hours. If you are scheduled for any medical procedure, inform your healthcare team that you are taking dolutegravir. This information is not a substitute for professional medical advice, diagnosis, or treatment.

Get Generic Dolutegravir - Shipping across Canada